

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先 健 科 技 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission of the SureCham™ Aortic Arch Single-Branch Stent Graft System into Special Examination and Approval Procedure for Innovative Medical Devices

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on 24 September 2026, the Company obtained formal written notice from the National Medical Products Administration (“**NMPA**”) confirming that the SureCham™ Aortic Arch Single-Branch Stent Graft System (the “**SureCham™ Single-Branch Stent Graft**” or the “**Product**”), jointly developed by the Company and Professor Shu Chang’s team of Fuwai Hospital, the Chinese Academy of Medical Sciences of the National Center for Cardiovascular Diseases, has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices (the “**Procedure**”). The Product is indicated for the treatment of aortic dissection involving the aortic arch. It is the 19th product of the Company having obtained admission to the Procedure.

In recent years, thoracic endovascular aortic repair (TEVAR) has become a major treatment modality for lesions involving the aortic arch. Traditional TEVAR often faces a trade-off between inadequate proximal anchoring and coverage of the left subclavian artery (LSA). Accordingly, the SureCham™ Single-Branch Stent Graft was developed. With its unique adjustable branch structure and fully single femoral access approach as its core design, it requires only a single femoral access to complete reconstruction of the main body and branch stent graft. While simplifying the procedure and reducing the risk of access-related complications, it provides a simpler and safer option for endovascular treatment of complex arch lesions.

The clinical advantages of SureCham™ Single-Branch Stent Graft are as follows:

1. Fully single femoral access, minimal trauma

The entire procedure can be completed through a single femoral access. The Product also facilitates cannulation of supra-aortic branches, and no untangling of the pre-loaded guidewire is required; procedural time is shorter; and access-related complications are fewer.

2. Adaptive and adjustable branch, broad adaptability

The flexible side branch can protrude outward or retract inward by 5 mm and can be adjusted bidirectionally in vivo. It flexibly adapts to various arch types and branch angles, broadening anatomical indications.

3. Adaptive navigation delivery system, precise positioning

The delivery system provides automatic navigation and self-positioning upon reaching the arch, enabling more precise release; the membrane constraint design allows rapid release with controllable positioning.

4. 8F ultra-thin outer sheath, easier operation

The outer sheath of the branch stent graft is only 8F, making delivery and release simpler and further reducing procedural difficulty.

The Product has been evaluated in extensive multicentre clinical studies nationwide. A total of 135 cases were successfully enrolled and completed at 24 centres across China. As of the date of this announcement, the clinical studies show that:

- Immediate technical success rate: 100%
- Freedom from major adverse events (MAE) within 30 days post-procedure: 97.78%

Among the 135 clinical cases, the shortest procedural time was only nine minutes. Postoperative CT follow-up showed that branch arteries remained patent in all cases and that the true lumen remodelling was good.

The Group possesses independent intellectual property rights to the Product. To date, the SureCham™ Single-Branch Stent Graft has been introduced into clinical use in certain countries and regions in Europe and Asia. Its outstanding performance and clinical value have received high recognition and widespread attention from international clinical experts. The Product, together with the innovative product matrix for chimney techniques for aortic arch branch reconstruction, the innovative product matrix for in situ fenestration techniques for aortic arch branch reconstruction, and the CS™ Concave Supra-arch Branched Stent-Graft System, will form a unique comprehensive endovascular treatment solution for aortic arch lesions, enabling vascular interventional physicians worldwide to address the challenges of total endovascular reconstruction of aortic arch branches more easily, flexibly and efficiently.

The Board believes that the admission of the Product into the Procedure not only signifies that the innovative design and clinical value of the SureCham™ Single-Branch Stent Graft have obtained authoritative recognition, but also marks that the Company, building on its established single-branch technological pathway, has further developed a more streamlined, more efficient and more readily standardised solution for aortic arch branch reconstruction. In addition, this will accelerate the clinical translation and commercialisation process of the Product, with a view to providing superior treatment options to a large number of patients suffering from aortic arch dissection at an earlier date.

By order of the Board

LifeTech Scientific Corporation

XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 24 September 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.